Elvis Temfack is a medical doctor at the Douala General Hospital, Douala, Cameroon, who currently is a PhD student in Infectious Disease and Microbiology at the Paris Descartes University and the Molecular Mycology unit of Institut Pasteur. He has different areas of expertise among which comprehensive patient care, clinical research and epidemiology. He is an active member of the HIV/AIDS therapeutic committee of the Douala General Hospital.
His main area of research interest is in infectious diseases particularly those associated with immune depression due to HIV infection, especially of the Central nervous system. His primary focus is on cryptococcal meningitis which is the leading cause of meningitis in adult African HIV-infected patients. He is presently the Research clinician and Douala site coordinator of the phase III multicentre clinical trial “Advancing Cryptococcal meningitis Treatment for Africa” (ACTA), a non-inferiority trial comparing a combination of oral regimen (fluconazole plus flucytosine) versus a regimen containing Amphotericin B administered for one week versus two weeks. This trial is jointly supported financially by the French Agency for HIV/AIDS and Hepatitis Research (ANRS): the Cameroon site (ANRS 12275 ACTA) and the Medical research Council of the UK (MRC): the other sites.
Elvis is also the local principal investigator of a prospective study entitled “Pre-antiretroviral therapy Cryptococcal Antigen Screening in AIDS (PreCASA)”, a project also supported by the ANRS (ANRS 12312 PreCASA).
Elvis obtained his MD degree at the Faculty of Medicine and Biomedical Sciences (FMBS) of the University of Yaoundé 1, Yaoundé, Cameroon in 2007. He obtained a Masters of Sciences (MSc) in the Control of Infectious Diseases at the London School of Hygiene and Tropical Medicine (LSHTM) of the University of London in 2010, studies supported financially by the University of North Carolina (UNC) at Chapel Hill Institute for Global Health & Infectious Diseases through the UNC AIDS International Training and Research Program: NIH/FIC 5 D43 TW001039-13.